Advanced search×

New frontiers in G protein-coupled receptor regulation of neurological disorders.

Stuart S Maudsley

CNS Neurol Disord Drug Targets 9(5):525 (2010) PMID 20632974

Version: za2963e q8za2 q8zb8 q8zcd q8zd8 q8zef q8zf2 q8zgb

Similar articles you may find interesting…

  1. AC-260584, an orally bioavailable M"1 muscarinic receptor allosteric agonist, improves cognitive performance in an animal model
    Stefania Risso Bradley, Jelveh Lameh, ... Douglas W Bonhaus

    Neuropharmacology 58(2):9 (2010) PMID 19835892

    We describe the receptor pharmacology and pro-cognitive action of the allosteric agonist AC-260584. Using in vitro cell-based assays with cell proliferation, phosphatidylinositol hydrolysis or calcium mobilization as endpoints, AC-260584 was found to be a potent (pEC(50) 7.6-7.7) and efficacious (90...
  2. Targeting opioid receptors: A new treatment for brain disorders.
    Shafiqur S Rahman

    CNS Neurol Disord Drug Targets 9(2):128 (2010) PMID 20401980

  3. Soothing the inflamed brain: effect of non-steroidal anti-inflammatory drugs on Alzheimer's disease pathology.
    J J M JJ Hoozemans, R R Veerhuis, ... P P Eikelenboom

    CNS Neurol Disord Drug Targets 10(1):57-67 (2011) PMID 21143138

    We will show that the primary targets of NSAIDs are involved in a pathological stage that precedes the clinical appearance of AD. The early, preclinical involvement of inflammation in AD explains why patients with clinical signs of AD do not benefit from anti-inflammatory treatment and suggests that...